We only have this paper's title and publication details.
Read it at the sourceObservational analysis shows potential cancer risk with glucagon-like peptide-1 receptor agonists, suggesting caution in treatment decisions.
None. (PROSPERO: CRD42024608365).
No takes yet. Share an insight, caveat, or question.
Ko et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: